Meiji Seika Kaisha has launched its oral cephem antibiotic Meiact (cefditoren pivoxil) in Japan, claiming that it is the most broad-spectrum of all available cephem antibiotics in the country. The company anticipates initial annual sales of 10 billion yen ($98.1 billion) and aims eventually to achieve sales of 20 billion yen, 10% of the cephem market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze